Richard Adcock - Dec 31, 2024 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol
IBRX
Transactions as of
Dec 31, 2024
Transactions value $
-$44,736
Form type
4
Date filed
1/3/2025, 04:54 PM
Previous filing
Feb 26, 2024
Next filing
Feb 12, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IBRX Common Stock Options Exercise $0 +34.5K +14.18% $0.00 278K Dec 31, 2024 Direct
transaction IBRX Common Stock Tax liability -$44.7K -17.5K -6.29% $2.56 260K Dec 31, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Restricted Stock Units Options Exercise $0 -34.5K -28.57% $0.00 86.2K Dec 31, 2024 Common Stock 34.5K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2 Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.